ReviewCurrent gastroenterology reports2025
Anal Squamous Intraepithelial Lesions: A Primer for Gastroenterologists.
Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to provide gastroenterologists a basic understanding of what anal squamous intraepithelial lesions (ASILs) are, how they develop, who are the high-risk populations, who and how to screen, and management of these lesions. RECENT
findingsHuman papilloma virus (HPV) infection is the most common cause of squamous cell carcinoma of the anus. Anal intraepithelial neoplasia is a precursor to the development of anal squamous cell carcinoma, and screening can lead to early detection and cure. Despite the availability of HPV vaccination for primary prevention, the mortality from squamous cell carcinoma of the anus continues to rise. ASILs are precursor lesions to anal cancer, and with proper detection and treatment, the risk of anal cancer progression can be lessened. We discuss the screening and surveillance of these lesions, and their further management when high-grade dysplasia or cancer develops.
Indexed as
Identifiers
41177815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.